New Science Signaling Publication

E-14 MSTP student Eli Grunblatt’s latest publication in Science Signaling‘s February 2019 issue explores small cell lung cancer. There has been limited improvement in first-line SCLC treatment in the past 30 years, and no targeted therapies are currently available. The high death rate and lack of treatment options have led the National Cancer Institute to designate SCLC as a “Recalcitrant Cancer” to underscore the need for new therapeutic frameworks. Their findings show promise for inhibiting tumor growth and even tumor regression.